REGULATORY
MHLW Unapproved Drug Panel Agrees on High Needs for 7 Additional Indications for Fertility Treatments
The Ministry of Health, Labor and Welfare’s (MHLW) Council on Unapproved Drugs and Indications with Unmet Medical Needs on September 13 agreed on high medical needs for six APIs for seven additional indications related to fertility treatments. This marked the…
To read the full story
Related Article
- MHLW Publishes Application Statuses for Infertility Treatments
October 7, 2021
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





